RÉSUMÉ
Cellular NAD+ is continuously degraded and synthesized under resting conditions. In mammals, NAD+ synthesis is primarily initiated from nicotinamide (Nam) by Nam phosphoribosyltransferase, whereas poly(ADP-ribose) polymerase 1 (PARP1) and 2 (PARP2), sirtuin1 (SIRT1), CD38, and sterile alpha and TIR motif containing 1 (SARM1) are involved in NAD+ breakdown. Using flux analysis with 2H-labeled Nam, we found that when mammalian cells were cultured in the absence of Nam, cellular NAD+ levels were maintained and NAD+ breakdown was completely suppressed. In the presence of Nam, the rate of NAD+ breakdown (RB) did not significantly change upon PARP1, PARP2, SIRT1, or SARM1 deletion, whereas stable expression of CD38 did not increase RB. However, RB in PARP1-deleted cells was much higher compared with that in wild-type cells, in which PARP1 activity was blocked with a selective inhibitor. In contrast, RB in CD38-overexpressing cells in the presence of a specific CD38 inhibitor was much lower compared with that in control cells. The results indicate that PARP1 deletion upregulates the activity of other NADases, whereas CD38 expression downregulates the activity of endogenous NADases, including PARP1 and PARP2. The rate of cellular NAD+ breakdown and the resulting NAD+ concentration may be maintained at a constant level, despite changes in the NAD+-degrading enzyme expression, through the compensatory regulation of NADase activity.
Sujet(s)
Antigènes CD38 , NAD , Poly (ADP-Ribose) polymerase-1 , Sirtuine-1 , NAD/métabolisme , Antigènes CD38/métabolisme , Antigènes CD38/génétique , Animaux , Poly (ADP-Ribose) polymerase-1/métabolisme , Sirtuine-1/métabolisme , Sirtuine-1/génétique , Nicotinamide/pharmacologie , Nicotinamide/métabolisme , Souris , Poly(ADP-ribose) polymerases/métabolisme , Humains , Nicotinamide phosphoribosyltransferase/métabolisme , Nicotinamide phosphoribosyltransferase/génétique , Délétion de gèneRÉSUMÉ
Type 2 diabetes mellitus is the most widespread type of diabetes, mainly affecting adults. Long-term complications are related to the progression of type 2 diabetes mellitus. Metformin is a key treatment option for type 2 diabetes. OBJECTIVES: To evaluate serum irisin, visfatin, and RBP4 levels and to determine the effects of metformin treatment on irisin, visfatin, and RBP4 levels in patients with type 2 diabetes mellitus (Type 2 DM). MATERIAL AND METHODS: A total of 70 patients with type 2 diabetes mellitus, aged between 48 and 82 years were enrolled in the current study. Serum collected and irisin, visfatin, and RBP4 levels were measured, in Type 2 DM patients and control, using the ELISA Kit. RESULTS: The findings observed that there were significantly increased levels of irisin, visfatin, and RBP4 in patients with T2DM when compared with control groups. After 3 months of metformin treatment, irisin levels significantly decreased irisin, visfatin, and RBP4 in patients with T2DM when compared before treatment. Receiver operator characteristic curve investigation shows the levels of visfatin, and irisin are the best biomarkers differentiating subjects with T2DM. CONCLUSION: In patients with type 2 diabetes, 3 months of treatment with metformin reduces levels of Irisin, Visfatin, and RBP4.The clinical significance of these findings remains to be investigated.
Sujet(s)
Marqueurs biologiques , Diabète de type 2 , Fibronectines , Hypoglycémiants , Metformine , Nicotinamide phosphoribosyltransferase , Protéines plasmatiques de liaison au rétinol , Humains , Metformine/usage thérapeutique , Diabète de type 2/traitement médicamenteux , Diabète de type 2/sang , Adulte d'âge moyen , Fibronectines/sang , Nicotinamide phosphoribosyltransferase/sang , Sujet âgé , Mâle , Femelle , Marqueurs biologiques/sang , Protéines plasmatiques de liaison au rétinol/métabolisme , Protéines plasmatiques de liaison au rétinol/analyse , Hypoglycémiants/usage thérapeutique , Sujet âgé de 80 ans ou plus , Adipokines/sang , CytokinesRÉSUMÉ
Evaluate the relationship between blood lead (Pb) levels and other biomedical markers and the risk of diabetes in gasoline station workers. The participants were separated into 2 groups: group A consisted of 26 workers from gasoline filling stations, while group B comprised 26 healthy individuals. Serum levels of malondialdehyde, IL-1ß, visfatin, insulin, fasting blood sugar, and vitamin D were assessed. Mean Pb level was significantly higher in group A compared to group B (almost 2.9 times higher levels) (14.43â ±â 1.01 vs 5.01â ±â 1.41, µg/dL). The levels of visfatin (23.19â ±â 0.96 vs 3.88â ±â 0.58, ng/mL), insulin (22.14â ±â 1.31 vs 11.26â ±â 0.75, mU/L), fasting blood sugar (118.4â ±â 26.1 vs 82.7â ±â 9.2, gm/dL), malondialdehyde (6.40â ±â 0.27 vs 1.62â ±â 0.21, nmol/mL), and IL-1ß (330.25â ±â 10.34 vs 12.35 ± 1.43, pg/mL) were significantly higher in group A, meanwhile; vitamin D (11.99â ±â 1.55 vs 35.41â ±â 3.16, ng/mL) were significantly lower in group A. A positive association exists between blood Pb levels and increased inflammatory markers. Lead exposure increases serum insulin and fasting blood sugar, which suggests that it is diabetogenic and that increased inflammation is a possible cause.
Sujet(s)
Glycémie , Essence , Hyperglycémie , Insuline , Plomb , Malonaldéhyde , Exposition professionnelle , Humains , Plomb/sang , Mâle , Exposition professionnelle/effets indésirables , Exposition professionnelle/analyse , Adulte , Études cas-témoins , Hyperglycémie/sang , Hyperglycémie/induit chimiquement , Hyperglycémie/épidémiologie , Études rétrospectives , Essence/effets indésirables , Glycémie/analyse , Insuline/sang , Malonaldéhyde/sang , Interleukine-1 bêta/sang , Marqueurs biologiques/sang , Adulte d'âge moyen , Nicotinamide phosphoribosyltransferase/sang , Vitamine D/sang , Femelle , Cytokines/sangRÉSUMÉ
Introduction: Children and young adults with congenital adrenal hyperplasia (CAH) are at increased risk of obesity and insulin resistance. There is evidence that children with CAH have increased visceral adiposity, which has been linked to metabolic syndrome and cardiovascular disease (CVD). The adipokine adiponectin has been shown to correlate with reduced metabolic risk, whereas the adipokines visfatin and leptin have been linked to visceral fat and adipocyte inflammation and can serve as biomarkers of increased metabolic risk. Few studies to date have characterized adipokine levels in children and young adults with congenital adrenal hyperplasia. We sought to investigate the relationship between adiponectin, leptin and visfatin levels to metabolic risk factors and androgen levels in children and young adults with CAH. Methods: Fasting blood was obtained for visfatin, leptin, adiponectin, glucose, insulin, CRP, lipid panel, total cholesterol (TC), triglycerides (TG) and HbA1c, as well as standard laboratory tests to assess adrenal control, from children with CAH due to 21-hydroxylase deficiency. HOMA-IR was calculated based on fasting glucose and insulin. Anthropomorphic measurements of BMI and waist-to-hip ratio were also obtained. Results: Adiponectin and androstenedione were inversely correlated (R = -0.57, p =0.016). There was a positive correlation between leptin and BMI percentile (R = 0.63, p <0.001) as well as leptin and HOMA-IR (R = 0.63, p <0.01). Glucocorticoid dose had a positive correlation with HOMA-IR (R=0.56, p = 0.021). Visfatin was inversely correlated with HDL cholesterol (R = -0.54, p = 0.026) and total cholesterol (R = -0.49, p <0.05). Overweight children and young adults had a significantly higher leptin (p = 0.02) and HOMA-IR (p=0.001) than non-overweight children and young adults. Conclusion: The inverse relationship between adiponectin and androstenedione suggests that better CAH control can reduce the risk of insulin resistance and metabolic syndrome. However, a high glucocorticoid dose appears to increase the risk of insulin resistance, underscoring the delicate balance required when treating CAH.
Sujet(s)
Adipokines , Hyperplasie congénitale des surrénales , Androgènes , Insulinorésistance , Nicotinamide phosphoribosyltransferase , Humains , Hyperplasie congénitale des surrénales/sang , Hyperplasie congénitale des surrénales/métabolisme , Enfant , Femelle , Mâle , Adolescent , Adipokines/sang , Nicotinamide phosphoribosyltransferase/sang , Jeune adulte , Androgènes/sang , Leptine/sang , Adulte , Marqueurs biologiques/sang , Adiponectine/sang , CytokinesRÉSUMÉ
Glyoxalase I (GLO1) is the primary enzyme for detoxification of the reactive dicarbonyl methylglyoxal (MG). Loss of GLO1 promotes accumulation of MG resulting in a recapitulation of diabetic phenotypes. We previously demonstrated attenuated GLO1 protein in skeletal muscle from individuals with type 2 diabetes (T2D). However, whether GLO1 attenuation occurs prior to T2D and the mechanisms regulating GLO1 abundance in skeletal muscle are unknown. GLO1 expression and activity were determined in skeletal muscle tissue biopsies from 15 lean healthy individuals (LH, BMI: 22.4 ± 0.7) and 5 individuals with obesity (OB, BMI: 32.4 ± 1.3). GLO1 protein was attenuated by 26 ± 0.3 % in OB compared to LH skeletal muscle (p = 0.019). Similar reductions for GLO1 activity were observed (p = 0.102). NRF2 and Keap1 expression were equivocal between groups despite a 2-fold elevation in GLO1 transcripts in OB skeletal muscle (p = 0.008). GLO1 knock-down (KD) in human immortalized myotubes promoted downregulation of muscle contraction and organization proteins indicating the importance of GLO1 expression for skeletal muscle function. SIRT1 KD had no effect on GLO1 protein or activity whereas, SIRT2 KD attenuated GLO1 protein by 28 ± 0.29 % (p < 0.0001) and GLO1 activity by 42 ± 0.12 % (p = 0.0150). KD of NAMPT also resulted in attenuation of GLO1 protein (28 ± 0.069 %, p = 0.003), activity (67 ± 0.09 %, p = 0.011) and transcripts (50 ± 0.13 %, p = 0.049). Neither the provision of the NAD+ precursors NR nor NMN were able to prevent this attenuation in GLO1 protein. However, NR did augment GLO1 specific activity (p = 0.022 vs NAMPT KD). These perturbations did not alter GLO1 acetylation status. SIRT1, SIRT2 and NAMPT protein levels were all equivocal in skeletal muscle tissue biopsies from individuals with obesity and lean individuals. These data implicate NAD+-dependent regulation of GLO1 in skeletal muscle independent of altered GLO1 acetylation and provide rationale for exploring NR supplementation to rescue attenuated GLO1 abundance and activity in conditions such as obesity.
Sujet(s)
Cytokines , Lactoyl glutathione lyase , Muscles squelettiques , Nicotinamide phosphoribosyltransferase , Obésité , Sirtuine-2 , Humains , Muscles squelettiques/métabolisme , Lactoyl glutathione lyase/métabolisme , Lactoyl glutathione lyase/génétique , Nicotinamide phosphoribosyltransferase/métabolisme , Nicotinamide phosphoribosyltransferase/génétique , Sirtuine-2/métabolisme , Sirtuine-2/génétique , Cytokines/métabolisme , Mâle , Obésité/métabolisme , Obésité/génétique , Diabète de type 2/métabolisme , Diabète de type 2/génétique , Facteur-2 apparenté à NF-E2/métabolisme , Facteur-2 apparenté à NF-E2/génétique , Femelle , Adulte , Protéine-1 de type kelch associée à ECH/métabolisme , Protéine-1 de type kelch associée à ECH/génétique , Régulation de l'expression des gènes , Adulte d'âge moyen , Sirtuine-1/métabolisme , Sirtuine-1/génétiqueRÉSUMÉ
Dendritic cells (DCs) are crucial in initiating and shaping both innate and adaptive immune responses. Clinical studies and experimental models have highlighted their significant involvement in various autoimmune diseases, positioning them as promising therapeutic targets. Nicotinamide (NAM), a form of vitamin B3, with its anti-inflammatory properties, has been suggested, while the involvement of NAM in DCs regulation remains elusive. Here, through analyzing publicly available databases, we observe substantial alterations in NAM levels and NAM metabolic pathways during DCs activation. Furthermore, we discover that NAM, but not Nicotinamide Mononucleotide (NMN), significantly inhibits DCs over-activation in vitro and in vivo. The suppression of DCs hyperactivation effectively alleviates symptoms of psoriasis. Mechanistically, NAM impairs DCs activation through a Poly (ADP-ribose) polymerases (PARPs)-NF-κB dependent manner. Notably, phosphoribosyl transferase (NAMPT) and PARPs are significantly upregulated in lipopolysaccharide (LPS)-stimulated DCs and psoriasis patients; elevated NAMPT and PARPs expression in psoriasis patients correlates with higher psoriasis area and severity index (PASI) scores. In summary, our findings underscore the pivotal role of NAM in modulating DCs functions and autoimmune disorders. Targeting the NAMPT-PARP axis emerges as a promising therapeutic approach for DC-related diseases.
Sujet(s)
Maladies auto-immunes , Cellules dendritiques , Nicotinamide , Nicotinamide phosphoribosyltransferase , Poly(ADP-ribose) polymerases , Psoriasis , Transduction du signal , Cellules dendritiques/effets des médicaments et des substances chimiques , Cellules dendritiques/métabolisme , Cellules dendritiques/immunologie , Nicotinamide/pharmacologie , Humains , Transduction du signal/effets des médicaments et des substances chimiques , Animaux , Psoriasis/traitement médicamenteux , Psoriasis/immunologie , Psoriasis/métabolisme , Maladies auto-immunes/traitement médicamenteux , Nicotinamide phosphoribosyltransferase/métabolisme , Souris , Poly(ADP-ribose) polymerases/métabolisme , Facteur de transcription NF-kappa B/métabolisme , Souris de lignée C57BL , LipopolysaccharidesRÉSUMÉ
Thalassemia is a group of genetic hematological conditions characterized by the defective synthesis of one or more hemoglobin chains. This genetic anomaly alters globin chain balance, causing hemolysis, ineffective erythropoiesis, and chronic inflammatory diseases. The proinflammatory adipocytokine visfatin is predominantly produced in visceral adipose tissue. Its evaluation in individuals with thalassemia may provide valuable insights into the assessment of disease severity. The aim of this study was to investigate the potential role of visfatin in the development of ß-thalassemia and its association with the severity of the illness. The study included 40 patients with ß-thalassemia and ten healthy individuals matched by age and sex. Serum visfatin level was measured using ELISA. We found that individuals with ß-thalassemia major had significantly higher levels of serum visfatin than those with ß-thalassemia minor and the control group (P < 0.001). A receiver operating characteristic curve revealed that serum visfatin levels were different in the three groups. Our results suggest that the serum level of visfatin is significantly correlated with the severity of ß-thalassemia.
Sujet(s)
Nicotinamide phosphoribosyltransferase , Indice de gravité de la maladie , bêta-Thalassémie , Humains , Nicotinamide phosphoribosyltransferase/sang , bêta-Thalassémie/sang , bêta-Thalassémie/génétique , Mâle , Femelle , Adulte , Études cas-témoins , Cytokines/sang , Jeune adulte , Courbe ROC , AdolescentRÉSUMÉ
RESEARCH AIM: Nicotinamide phosphoribosyltransferase (Nampt) is an adipocytokine that is elevated in obesity, type 2 diabetes and increased levels are associated with inflammatory processes. Nampt serum concentrations have been suggested to follow a diurnal rhythm peaking in the afternoon in lean males. However, no data exists regarding the effects of gender and body weight. MATERIAL AND METHODS: We measured Nampt serum levels over 24 h in a cohort of healthy individuals living with either normal weight or obesity. Furthermore, effects of meals, oral glucose tolerance test and physical exercise on Nampt concentrations were evaluated. Correlation analyses to other hormonal- and lab parameters and anthropometric measurements were performed. RESULTS: Nampt showed a diurnal rhythm with increased levels at daytime and a peak in the early afternoon. This diurnal rhythm was significant for all groups but obese males. The Nampt amplitude, measured both relatively and absolutely, was significantly higher in females than in males. Meals did not influence Nampt serum levels, whereas physical exercise and an OGTT did significantly influence Nampt serum levels. CONCLUSION: In conclusion, we found gender specific differences in Nampt amplitude and coefficient variation with both being higher in females. The circadian rhythm of Nampt was independent of gender in healthy lean individuals, whereas it was disturbed in men with obesity.
Sujet(s)
Rythme circadien , Cytokines , Exercice physique , Nicotinamide phosphoribosyltransferase , Obésité , Humains , Nicotinamide phosphoribosyltransferase/sang , Mâle , Femelle , Rythme circadien/physiologie , Adulte , Obésité/sang , Cytokines/sang , Facteurs sexuels , Exercice physique/physiologie , Poids/physiologie , Hyperglycémie provoquée , Adulte d'âge moyen , Jeune adulteRÉSUMÉ
ß-Nicotinamide mononucleotide (NMN) is a biologically active nucleotide that regulates the physiological metabolism of the body by rapidly increasing nicotinamide adenine dinucleotide (NAD+). To determine the safety and biological activity of NMN resources, we constructed a recombinant strain of P. pastoris that heterologously expresses nicotinamide-phosphate ribosyltransferase (NAMPT), and subsequently catalyzed and purified the expressed product to obtain NMN. Consequently, this study established a high-fat diet (HFD) obese model to investigate the lipid-lowering activity of NMN. The findings showed that NMN supplementation directly increased the NAD+ levels, and reduced HFD-induced liver injury and lipid deposition. NMN treatment significantly decreased total cholesterol (TC) and triglyceride (TG) in serum and liver, as well as alanine aminotransferase (ALT) and insulin levels in serum (p < .05 or p < .01). In conclusion, this study combined synthetic biology with nutritional evaluation to confirm that P. pastoris-generated NMN modulated lipid metabolism in HFD mice, offering a theoretical framework and evidence for the application of microbially created NMN.
Sujet(s)
Alimentation riche en graisse , Métabolisme lipidique , Foie , Souris de lignée C57BL , Nicotinamide mononucléotide , Animaux , Nicotinamide mononucléotide/métabolisme , Nicotinamide mononucléotide/pharmacologie , Métabolisme lipidique/effets des médicaments et des substances chimiques , Souris , Foie/métabolisme , Mâle , Nicotinamide phosphoribosyltransferase/métabolismeRÉSUMÉ
Chronic Hepatitis B virus (CHB) infection is a global health challenge, causing damage ranging from hepatitis to cirrhosis and hepatocellular carcinoma. In our study, single-cell RNA sequencing (scRNA-seq) analysis was performed in livers from mice models with chronic inflammation induced by CHB infection and we found that endothelial cells (ECs) exhibited the largest number of differentially expressed genes (DEGs) among all ten cell types. NF-κB signaling was activated in ECs to induce cell dysfunction and subsequent hepatic inflammation, which might be mediated by the interaction of macrophage-derived and cholangiocyte-derived VISFATIN/Nampt signaling. Moreover, we divided ECs into three subclusters, including periportal ECs (EC_Z1), midzonal ECs (EC_Z2), and pericentral ECs (EC_Z3) according to hepatic zonation. Functional analysis suggested that pericentral ECs and midzonal ECs, instead of periportal ECs, were more vulnerable to HBV infection, as the VISFATIN/Nampt- NF-κB axis was mainly altered in these two subpopulations. Interestingly, pericentral ECs showed increasing communication with macrophages and cholangiocytes via the Nampt-Insr and Nampt-Itga5/Itgb1 axis upon CHB infection, which contribute to angiogenesis and vascular capillarization. Additionally, ECs, especially pericentral ECs, showed a close connection with nature killer (NK) cells and T cells via the Cxcl6-Cxcr6 axis, which is involved in shaping the microenvironment in CHB mice livers. Thus, our study described the heterogeneity and functional alterations of three subclusters in ECs. We revealed the potential role of VISFATIN/Nampt signaling in modulating ECs characteristics and related hepatic inflammation, and EC-derived chemokine Cxcl16 in shaping NK and T cell recruitment, providing key insights into the multifunctionality of ECs in CHB-associated pathologies.
Sujet(s)
Cellules endothéliales , Hépatite B chronique , Analyse sur cellule unique , Animaux , Hépatite B chronique/virologie , Hépatite B chronique/génétique , Hépatite B chronique/métabolisme , Souris , Cellules endothéliales/métabolisme , Cellules endothéliales/virologie , Analyse de séquence d'ARN , Virus de l'hépatite B/génétique , Virus de l'hépatite B/physiologie , Transduction du signal , Foie/métabolisme , Foie/virologie , Foie/anatomopathologie , Facteur de transcription NF-kappa B/métabolisme , Mâle , Nicotinamide phosphoribosyltransferase/métabolisme , Nicotinamide phosphoribosyltransferase/génétique , Modèles animaux de maladie humaine , Souris de lignée C57BL , HumainsRÉSUMÉ
Triple Negative Breast Cancer (TNBC) is the most aggressive breast cancer subtype suffering from limited targeted treatment options. Following recent reports correlating Fibroblast growth factor-inducible 14 (Fn14) receptor overexpression in Estrogen Receptor (ER)-negative breast cancers with metastatic events, we show that Fn14 is specifically overexpressed in TNBC patients and associated with poor survival. We demonstrate that constitutive Fn14 signalling rewires the transcriptomic and epigenomic landscape of TNBC, leading to enhanced tumour growth and metastasis. We further illustrate that such mechanisms activate TNBC-specific super enhancers (SE) to drive the transcriptional activation of cancer dependency genes via chromatin looping. In particular, we uncover the SE-driven upregulation of Nicotinamide phosphoribosyltransferase (NAMPT), which promotes NAD+ and ATP metabolic reprogramming critical for filopodia formation and metastasis. Collectively, our study details the complex mechanistic link between TWEAK/Fn14 signalling and TNBC metastasis, which reveals several vulnerabilities which could be pursued for the targeted treatment of TNBC patients.
Sujet(s)
Cytokine TWEAK , Régulation de l'expression des gènes tumoraux , Nicotinamide phosphoribosyltransferase , Transduction du signal , Récepteur TWEAK , Tumeurs du sein triple-négatives , Tumeurs du sein triple-négatives/métabolisme , Tumeurs du sein triple-négatives/génétique , Tumeurs du sein triple-négatives/anatomopathologie , Humains , Récepteur TWEAK/métabolisme , Récepteur TWEAK/génétique , Femelle , Cytokine TWEAK/métabolisme , Cytokine TWEAK/génétique , Nicotinamide phosphoribosyltransferase/métabolisme , Nicotinamide phosphoribosyltransferase/génétique , Animaux , Lignée cellulaire tumorale , Souris , Métastase tumorale , Cytokines/métabolisme , Éléments activateurs (génétique)/génétiqueRÉSUMÉ
HIV disease remains prevalent in the United States and is particularly prevalent in sub-Saharan Africa. Recent investigations revealed that mitochondrial dysfunction in kidney contributes to HIV-associated nephropathy (HIVAN) in Tg26 transgenic mice. We hypothesized that nicotinamide adenine dinucleotide (NAD) deficiency contributes to energetic dysfunction and progressive tubular injury. We investigated metabolomic mechanisms of HIVAN tubulopathy. Tg26 and wild-type (WT) mice were treated with the farnesoid X receptor (FXR) agonist INT-747 or nicotinamide riboside (NR) from 6 to 12 wk of age. Multiomic approaches were used to characterize kidney tissue transcriptomes and metabolomes. Treatment with INT-747 or NR ameliorated kidney tubular injury, as shown by serum creatinine, the tubular injury marker urinary neutrophil-associated lipocalin, and tubular morphometry. Integrated analysis of metabolomic and transcriptomic measurements showed that NAD levels and production were globally downregulated in Tg26 mouse kidneys, especially nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme in the NAD salvage pathway. Furthermore, NAD-dependent deacetylase sirtuin3 activity and mitochondrial oxidative phosphorylation activity were lower in ex vivo proximal tubules from Tg26 mouse kidneys compared with those of WT mice. Restoration of NAD levels in the kidney improved these abnormalities. These data suggest that NAD deficiency might be a treatable target for HIVAN.NEW & NOTEWORTHY The study describes a novel investigation that identified nicotinamide adenine dinucleotide (NAD) deficiency in a widely used HIV-associated nephropathy (HIVAN) transgenic mouse model. We show that INT-747, a farnesoid X receptor agonist, and nicotinamide riboside (NR), a precursor of nicotinamide, each ameliorated HIVAN tubulopathy. Multiomic analysis of mouse kidneys revealed that NAD deficiency was an upstream metabolomic mechanism contributing to HIVAN tubulopathy.
Sujet(s)
Néphropathie associée au SIDA , Souris transgéniques , NAD , Nicotinamide , Composés de pyridinium , Sirtuine-3 , Animaux , NAD/métabolisme , Néphropathie associée au SIDA/métabolisme , Néphropathie associée au SIDA/génétique , Néphropathie associée au SIDA/anatomopathologie , Nicotinamide/analogues et dérivés , Nicotinamide/pharmacologie , Composés de pyridinium/pharmacologie , Sirtuine-3/métabolisme , Sirtuine-3/génétique , Sirtuine-3/déficit , Modèles animaux de maladie humaine , Nicotinamide phosphoribosyltransferase/métabolisme , Nicotinamide phosphoribosyltransferase/génétique , Souris , Mitochondries/métabolisme , Mitochondries/anatomopathologie , Évolution de la maladie , Métabolomique , Récepteurs cytoplasmiques et nucléaires/métabolisme , Récepteurs cytoplasmiques et nucléaires/génétique , Récepteurs cytoplasmiques et nucléaires/déficit , Rein/métabolisme , Rein/anatomopathologie , Rein/effets des médicaments et des substances chimiques , Mâle , Souris de lignée C57BL , Cytokines/métabolismeRÉSUMÉ
BACKGROUND: Long noncoding RNA (lncRNA) and mRNA profiles in leukocytes have shown potential as biomarkers for acute ischemic stroke (AIS). This study aimed to identify altered lncRNA and target mRNA profiles in peripheral blood leukocytes as biomarkers and to assess the diagnostic value and association with AIS prognosis. METHODS AND RESULTS: Differentially expressed lncRNAs (DElncRNAs) and differentially expressed target mRNAs (DEmRNAs) were screened by RNA sequencing in the discovery set, which consisted of 10 patients with AIS and 20 controls. Validation sets consisted of a multicenter (311 AIS versus 303 controls) and a nested case-control study (351 AIS versus 352 controls). The discriminative value of DElncRNAs and DEmRNAs added to the traditional risk factors was estimated with the area under the curve. NAMPT-AS, FARP1-AS1, FTH1, and NAMPT were identified in the multicenter case-control study (P<0.05). LncRNA NAMPT-AS was associated with cis-target mRNA NAMPT and trans-target mRNA FTH1 in all validation sets (P<0.001). Similarly, AIS cases exhibited upregulated lncRNA FARP-AS1 and FTH1 expression (P<0.001) in the nested case-control study (P<0.001). Furthermore, lncRNA FARP1-AS1 expression was upregulated in AIS patients at discharge with an unfavorable outcome (P<0.001). Positive correlations were found between NAMPT expression level and NIHSS scores of AIS patients (P<0.05). Adding 2 lncRNAs and 2 target mRNAs to the traditional risk factor model improved area under the curve by 22.8% and 5.2% in the multicenter and the nested case-control studies, respectively. CONCLUSIONS: lncRNA NAMPT-AS and FARP1-AS1 have potential as diagnostic biomarkers for AIS and exhibit good performance when combined with target mRNA NAMPT and FTH1.
Sujet(s)
Marqueurs biologiques , Accident vasculaire cérébral ischémique , Leucocytes , ARN long non codant , ARN messager , Humains , ARN long non codant/sang , ARN long non codant/génétique , Mâle , Femelle , Accident vasculaire cérébral ischémique/génétique , Accident vasculaire cérébral ischémique/diagnostic , Accident vasculaire cérébral ischémique/sang , ARN messager/sang , ARN messager/génétique , Adulte d'âge moyen , Études cas-témoins , Pronostic , Leucocytes/métabolisme , Sujet âgé , Marqueurs biologiques/sang , Nicotinamide phosphoribosyltransferase/génétique , Nicotinamide phosphoribosyltransferase/sang , Cytokines/sang , Cytokines/génétique , Reproductibilité des résultatsRÉSUMÉ
Gymnema sylvestre (GS) and berberine (BBR) are natural products that have demonstrated therapeutic potential for the management of obesity and its comorbidities, as effective and safe alternatives to synthetic drugs. Although their anti-obesogenic and antidiabetic properties have been widely studied, comparative research on their impact on the gene expression of adipokines, such as resistin (Res), omentin (Ome), visfatin (Vis) and apelin (Ap), has not been reported. METHODOLOGY: We performed a comparative study in 50 adult Mexican patients with obesity treated with GS or BBR for 3 months. The baseline and final biochemical parameters, body composition, blood pressure, gene expression of Res, Ome, Vis, and Ap, and safety parameters were evaluated. RESULTS: BBR significantly decreased (p < 0.05) body weight, blood pressure and Vis and Ap gene expression and increased Ome, while GS decreased fasting glucose and Res gene expression (p < 0.05). A comparative analysis of the final measurements revealed a lower gene expression of Ap and Vis (p < 0.05) in patients treated with BBR than in those treated with GS. The most frequent adverse effects in both groups were gastrointestinal symptoms, which attenuated during the first month of treatment. CONCLUSION: In patients with obesity, BBR has a better effect on body composition, blood pressure, and the gene expression of adipokines related to metabolic risk, while GS has a better effect on fasting glucose and adipokines related to insulin resistance, with minimal side effects.
Sujet(s)
Adipokines , Berbérine , Composition corporelle , Gymnema sylvestre , Obésité , Résistine , Humains , Mâle , Femelle , Adulte , Obésité/traitement médicamenteux , Obésité/métabolisme , Adipokines/sang , Adipokines/métabolisme , Composition corporelle/effets des médicaments et des substances chimiques , Adulte d'âge moyen , Berbérine/pharmacologie , Résistine/sang , Résistine/métabolisme , Apeline , Pression sanguine/effets des médicaments et des substances chimiques , Nicotinamide phosphoribosyltransferase/métabolisme , Cytokines/métabolisme , Cytokines/sang , Extraits de plantes/pharmacologie , Glycémie/effets des médicaments et des substances chimiques , Glycémie/métabolisme , Lectines , Protéines liées au GPI/métabolisme , Protéines liées au GPI/génétique , Agents antiobésité/pharmacologie , Agents antiobésité/usage thérapeutiqueRÉSUMÉ
Tissue-specific deficiency of nicotinamide phosphoribosyl transferase (NAMPT), the rate-limiting enzyme of the nicotinamide adenine dinucleotide (NAD+)-salvage pathway, causes a decrease of NAD+ in the tissue, resulting in functional abnormalities. The NAD+-salvage pathway is drastically activated in the mammary gland during lactation, but the significance of this has not been established. To investigate the impact of NAD+ perturbation in the mammary gland, we generated two new lines of mammary gland epithelial-cell-specific Nampt-knockout mice (MGKO). LC-MS/MS analyses confirmed that the levels of NAD+ and its precursor nicotinamide mononucleotide (NMN) were significantly increased in lactating mammary glands. We found that murine milk contained a remarkably high level of NMN. MGKO exhibited a significant decrease in tissue NAD+ and milk NMN levels in the mammary gland during lactation periods. Despite the decline in NAD+ levels, the mammary glands of MGKO appeared to develop normally. Transcriptome analysis revealed that the gene profiles of MGKO were indistinguishable from those of their wild-type counterparts, except for Nampt. Although the NMN levels in milk from MGKO were decreased, the metabolomic profile of milk was otherwise unaltered. The mammary gland also contains adipocytes, but adipocyte-specific deficiency of Nampt did not affect mammary gland NAD+ metabolism or mammary gland development. These results demonstrate that the NAD+ -salvage pathway is activated in mammary epithelial cells during lactation and suggest that this activation is required for production of milk NMN rather than mammary gland development. Our MGKO mice could be a suitable model for exploring the potential roles of NMN in milk.
Sujet(s)
Cellules épithéliales , Lactation , Glandes mammaires animales , Souris knockout , Lait , Nicotinamide mononucléotide , Nicotinamide phosphoribosyltransferase , Animaux , Nicotinamide phosphoribosyltransferase/métabolisme , Nicotinamide phosphoribosyltransferase/génétique , Nicotinamide mononucléotide/métabolisme , Glandes mammaires animales/métabolisme , Femelle , Cellules épithéliales/métabolisme , Lait/métabolisme , Souris , Lactation/métabolisme , Cytokines/métabolisme , NAD/métabolisme , Souris de lignée C57BLRÉSUMÉ
BACKGROUND & AIMS: Extracellular nicotinamide phosphoribosyltransferase (eNAMPT) has long been recognized as an adipokine. However, the exact role of eNAMPT in alcoholic liver disease (ALD) and its relevance to brown adipose tissue (BAT) remain largely unknown. This study aimed to evaluate the impact of eNAMPT on liver function and the underlying mechanisms involved in BAT-Liver communication. METHODS: Serum eNAMPT levels were detected in the serum of both ALD patients and mice. Chronic and binge ethanol feeding was used to induce alcoholic liver injury in mice. An eNAMPT antibody, a coculture model of brown adipocytes and hepatocytes, and BAT-specific Nampt knockdown mice were used to investigate the role of eNAMPT in ALD. RESULTS: Serum eNAMPT levels are elevated in ALD patients and are significantly positively correlated with the liver injury index. In ALD mice, neutralizing eNAMPT reduced the elevated levels of circulating eNAMPT induced by ethanol and attenuated liver injury. In vitro experiments revealed that eNAMPT induced hepatocyte ferroptosis through the TLR4-dependent mitochondrial ROS-induced ferritinophagy pathway. Furthermore, ethanol stimulated eNAMPT secretion from brown adipocytes but not from other adipocytes. In the coculture model, ethanol-induced release of eNAMPT from brown adipocytes promoted hepatocyte ferroptosis. In BAT-specific Nampt-knockdown mice, ethanol-induced eNAMPT secretion was significantly reduced, and alcoholic liver injury were attenuated. These effects can be reversed by intraperitoneal injection of eNAMPT. CONCLUSION: Inhibition of ethanol-induced eNAMPT secretion from BAT attenuates liver injury and ferroptosis. Our study reveals a previously uncharacterized critical role of eNAMPT-mediated BAT-Liver communication in ALD and highlights its potential as a therapeutic target.
Sujet(s)
Tissu adipeux brun , Éthanol , Ferroptose , Maladies alcooliques du foie , Foie , Nicotinamide phosphoribosyltransferase , Animaux , Souris , Ferroptose/effets des médicaments et des substances chimiques , Humains , Nicotinamide phosphoribosyltransferase/métabolisme , Nicotinamide phosphoribosyltransferase/génétique , Maladies alcooliques du foie/métabolisme , Maladies alcooliques du foie/anatomopathologie , Maladies alcooliques du foie/étiologie , Foie/métabolisme , Foie/effets des médicaments et des substances chimiques , Foie/anatomopathologie , Tissu adipeux brun/métabolisme , Tissu adipeux brun/effets des médicaments et des substances chimiques , Hépatocytes/métabolisme , Hépatocytes/effets des médicaments et des substances chimiques , Mâle , Modèles animaux de maladie humaine , CytokinesRÉSUMÉ
OBJECTIVE: Nonalcoholic fatty liver disease is a chronic liver disease and a growing global epidemic. The aim of this study was to investigate the association between a visfatin gene (NAMPT) variant and nonalcoholic fatty liver disease, owing to the connection between this disease and insulin resistance, obesity, inflammation, and oxidative stress, and the role of visfatin in these metabolic disorders. METHODS: In the present case-control study, we enrolled 312 genetically unrelated individuals, including 154 patients with biopsy-proven nonalcoholic fatty liver disease and 158 controls. The rs2058539 polymorphism of NAMPT gene was genotyped using the PCR-RFLP method. RESULTS: Genotype and allele distributions of NAMPT gene rs2058539 polymorphism conformed to the Hardy-Weinberg equilibrium both in the case and control groups (p>0.05). The distribution of NAMPT rs2058539 genotypes and alleles differed significantly between the cases with nonalcoholic fatty liver disease and controls. The "CC" genotype of the NAMPT rs2058539 compared with "AA" genotype was associated with a 2.5-fold increased risk of nonalcoholic fatty liver disease after adjustment for confounding factors [p=0.034; odds ratio (OR)=2.52, 95% confidence interval (CI)=1.36-4.37]. Moreover, the NAMPT rs2058539 "C" allele was significantly overrepresented in the nonalcoholic fatty liver disease patients than controls (p=0.022; OR=1.77, 95%CI=1.14-2.31). CONCLUSION: Our findings indicated for the first time that the NAMPT rs2058539 "CC" genotype is a marker of increased nonalcoholic fatty liver disease susceptibility; however, it needs to be supported by further investigations in other populations.
Sujet(s)
Cytokines , Prédisposition génétique à une maladie , Génotype , Nicotinamide phosphoribosyltransferase , Stéatose hépatique non alcoolique , Polymorphisme de nucléotide simple , Humains , Nicotinamide phosphoribosyltransferase/génétique , Stéatose hépatique non alcoolique/génétique , Femelle , Mâle , Études cas-témoins , Adulte d'âge moyen , Facteurs de risque , Adulte , Prédisposition génétique à une maladie/génétique , Cytokines/génétique , Fréquence d'allèle/génétique , Allèles , Polymorphisme de restriction , Réaction de polymérisation en chaîneRÉSUMÉ
Nicotinamide mononucleotide (NMN) serves as a precursor for NAD+ synthesis and has been shown to have positive effects on the human body. Previous research has predominantly focused on the nicotinamide phosphoribosyltransferase-mediated route (NadV-mediated route) for NMN biosynthesis. In this study, we have explored the de novo NMN biosynthesis route as an alternative pathway to enhance NMN production. Initially, we systematically engineered Escherichia coli to enhance its capacity for NMN synthesis and accumulation, resulting in a remarkable over 100-fold increase in NMN yield. Subsequently, we progressively enhanced the de novo NMN biosynthesis route to further augment NMN production. We screened and identified the crucial role of MazG in catalyzing the enzymatic cleavage of NAD+ to NMN. And the de novo NMN biosynthesis route was optimized and integrated with the NadV-mediated NMN biosynthetic pathways, leading to an intracellular concentration of 844.10 ± 17.40 µM NMN. Furthermore, the introduction of two transporters enhanced the uptake of NAM and the excretion of NMN, resulting in NMN production of 1293.73 ± 61.38 µM. Finally, by engineering an E. coli strain with optimized PRPP synthetase, we achieved the highest NMN production, reaching 3067.98 ± 27.25 µM after 24 h of fermentation at the shake flask level. In addition to constructing an efficient E. coli cell factory for NMN production, our findings provide new insights into understanding the NAD+ salvage pathway and its role in energy metabolism within E. coli.
Sujet(s)
Escherichia coli , Génie métabolique , NAD , Nicotinamide mononucléotide , Escherichia coli/métabolisme , Escherichia coli/génétique , Nicotinamide mononucléotide/métabolisme , Génie métabolique/méthodes , NAD/métabolisme , Protéines Escherichia coli/métabolisme , Protéines Escherichia coli/génétique , Nicotinamide phosphoribosyltransferase/métabolisme , Nicotinamide phosphoribosyltransferase/génétique , Voies de biosynthèse/génétiqueRÉSUMÉ
N-Pyridinylthiophene carboxamide (compound 21) displays activity against peripheral nerve sheath cancer cells and mouse xenografts by an unknown mechanism. Through medicinal chemistry, we identified a more active derivative, compound 9, and found that only analogues with structures similar to nicotinamide retained activity. Genetic screens using compound 9 found that both NAMPT and NMNAT1, enzymes in the NAD salvage pathway, are necessary for activity. Compound 9 is metabolized by NAMPT and NMNAT1 into an adenine dinucleotide (AD) derivative in a cell-free system, cultured cells, and mice, and inhibition of this metabolism blocked compound activity. AD analogues derived from compound 9 inhibit IMPDH in vitro and cause cell death by inhibiting IMPDH in cells. These findings nominate these compounds as preclinical candidates for the development of tumor-activated IMPDH inhibitors to treat neuronal cancers.
Sujet(s)
NAD , Nicotinamide , Thiophènes , Animaux , NAD/métabolisme , Humains , Souris , Nicotinamide/analogues et dérivés , Nicotinamide/métabolisme , Nicotinamide/pharmacologie , Nicotinamide/composition chimique , Thiophènes/pharmacologie , Thiophènes/composition chimique , Thiophènes/métabolisme , Lignée cellulaire tumorale , IMP dehydrogenase/antagonistes et inhibiteurs , IMP dehydrogenase/métabolisme , Antinéoplasiques/pharmacologie , Antinéoplasiques/composition chimique , Nicotinamide phosphoribosyltransferase/métabolisme , Nicotinamide phosphoribosyltransferase/antagonistes et inhibiteurs , Tumeurs des gaines nerveuses/traitement médicamenteux , Tumeurs des gaines nerveuses/métabolisme , Tumeurs des gaines nerveuses/anatomopathologie , Antienzymes/pharmacologie , Antienzymes/composition chimique , Nicotinamide nucleotide adenylyltransferase/métabolisme , Nicotinamide nucleotide adenylyltransferase/antagonistes et inhibiteursRÉSUMÉ
The malignancy of breast cancer poses a global challenge, with existing treatments often falling short of desired efficacy. Extensive research has underscored the effectiveness of targeting the metabolism of nicotinamide adenine dinucleotide (NAD), a pivotal molecule crucial for cancer cell survival and growth, as a promising anticancer strategy. Within mammalian cells, sustaining optimal NAD concentrations relies on two key enzymes, namely nicotinamide phosphoribosyltransferase (NAMPT) and poly(ADP-ribose) polymer 1 (PARP1). Recent studies have accentuated the potential benefits of combining NAMPT inhibitors and PARP1 inhibitors to enhance therapeutic outcomes, particularly in breast cancer. In this study, we designed and synthesized eleven novel NAMPT/PARP1 dual-target inhibitors. Among them, compound DDY02 exhibited acceptable inhibitory activities against both NAMPT and PARP1, with IC50 values of 0.01 and 0.05 µM, respectively. Moreover, in vitro evaluations revealed that treatment with DDY02 resulted in proliferation inhibition, NAD depletion, DNA damage, apoptosis, and migration inhibition in MDA-MB-468 cells. These results posit DDY02, by targeting NAD metabolism through inhibiting both NAMPT and PARP1, as a promising lead compound for the development of breast cancer therapy.